Leiden/Amsterdam Center for Drug Research (LACDR) Department of Pharmacochemistry, Faculty of Chemistry Vrije Universiteit De Boelelaan 1083 Amsterdam 1081 HV The Netherlands.
Mediators Inflamm. 1996;5(6):393-416. doi: 10.1155/S0962935196000567.
Five to 10% of the human population have a disorder of the respiratory tract called 'asthma'. It has been known as a potentially dangerous disease for over 2000 years, as it was already described by Hippocrates and recognized as a disease entity by Egyptian and Hebrew physicians. At the beginning of this decade, there has been a fundamental change in asthma management. The emphasis has shifted from symptom relief with bronchodilator therapies (e.g. beta(2)-agonists) to a much earlier introduction of anti-inflammatory treatment (e.g. corticosteroids). Asthma is now recognized to be a chronic inflammatory disease of the airways, involving various inflammatory cells and their mediators. Although asthma has been the subject of many investigations, the exact role of the different inflammatory cells has not been elucidated completely. Many suggestions have been made and several cells have been implicated in the pathogenesis of asthma, such as the eosinophils, the mast cells, the basophils and the lymphocytes. To date, however, the relative importance of these cells is not completely understood. The cell type predominantly found in the asthmatic lung is the eosinophil and the recruitment of these eosinophils can be seen as a characteristic of asthma. In recent years much attention is given to the role of the newly identified chemokines in asthma pathology. Chemokines are structurally and functionally related 8-10 kDa peptides that are the products of distinct genes clustered on human chromosomes 4 and 17 and can be found at sites of inflammation. They form a superfamily of proinflammatory mediators that promote the recruitment of various kinds of leukocytes and lymphocytes. The chemokine superfamily can be divided into three subgroups based on overall sequence homology. Although the chemokines have highly conserved amino acid sequences, each of the chemokines binds to and induces the chemotaxis of particular classes of white blood cells. Certain chemokines stimulate the recruitment of multiple cell types including monocytes, lymphocytes, basophils, and eosinophils, which are important cells in asthma. Intervention in this process, by the development of chemokine antagonists, might be the key to new therapy. In this review we present an overview of recent developments in the field of chemokines and their role in inflammations as reported in literature.
人群中有 5%至 10%患有呼吸道疾病,称为“哮喘”。2000 多年来,哮喘一直被认为是一种潜在的危险疾病,因为它已经被希波克拉底描述过,并被埃及和希伯来医生认作一种疾病实体。在这十年的开始,哮喘的管理发生了根本性的变化。重点已经从支气管扩张剂治疗(例如β2-激动剂)的症状缓解转移到更早地引入抗炎治疗(例如皮质类固醇)。现在,哮喘被认为是一种气道慢性炎症性疾病,涉及各种炎症细胞及其介质。尽管哮喘已经成为许多研究的主题,但不同炎症细胞的确切作用尚未完全阐明。已经提出了许多建议,并且已经有几种细胞被牵连到哮喘的发病机制中,例如嗜酸性粒细胞、肥大细胞、嗜碱性粒细胞和淋巴细胞。然而,迄今为止,这些细胞的相对重要性尚不完全清楚。在哮喘患者的肺部中发现的主要细胞类型是嗜酸性粒细胞,并且这些嗜酸性粒细胞的募集可以被视为哮喘的特征。近年来,人们对新发现的趋化因子在哮喘病理中的作用给予了极大关注。趋化因子是结构和功能上相关的 8-10 kDa 肽,是人类染色体 4 和 17 上簇集的不同基因的产物,可在炎症部位发现。它们形成了一个促炎介质的超家族,促进了各种白细胞和淋巴细胞的募集。趋化因子超家族可以根据总体序列同源性分为三个亚组。尽管趋化因子具有高度保守的氨基酸序列,但每种趋化因子都结合并诱导特定类别的白细胞的趋化性。某些趋化因子刺激包括单核细胞、淋巴细胞、嗜碱性粒细胞和嗜酸性粒细胞在内的多种细胞类型的募集,这些细胞在哮喘中是重要的。通过开发趋化因子拮抗剂来干预这一过程可能是新疗法的关键。在这篇综述中,我们介绍了趋化因子及其在文献报道的炎症中的作用的最新研究进展。